Phyllodes tumor of the breast is an infrequently encountered fibroepithelial neoplasm, which accounts for 0.3–1% of all tumors. Few case reports have described the occurrence of giant phyllodes tumor. To our knowledge, about 20% of phyllodes tumors would be considered giant benign. Complete surgical excision is the standard of care for giant benign phyllodes tumors; axillary lymph node metastasis is rare, and dissection should be limited to patients with pathologic evidence of tumor in the lymph nodes. We report the case of a 40-year-old Mexican woman with giant mammary tumor who underwent a right total mastectomy. The pathology results showed a benign phyllodes tumor 4,857 g in weight and 40.2 × 36.3 × 15 cm in size. We do not suggest adjuvant radiation therapy for patients with benign phyllodes tumors that are widely excised. A review of the pertinent literature was performed.
Introduction. The prognostic nutritional index (PNI) is a convenient and accessible tool that reflects the nutritional and immunological conditions of patients with solid tumors. PNI is calculated based on the total lymphocyte count and serum albumin level. There is not an optimal well established cutoff value. Low PNI has been associated with lower overall and disease-free survival (OS and DFS) in breast cancer patients, however, there is no information regarding this prognostic value in patients from Mexico. The aim of this study was to analyze the association between PNI and survival of breast cancer patients from Mexico. Methods. We retrospectively analyzed medical records of patients with histologically confirmed breast cancer treated at Medica Sur Oncology Center in Mexico City between January 2008 to December 2019. PNI was calculated using the following formula: 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count (mm3). Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal PNI cutoff value. The primary endpoint was OS. The secondary endpoint was DFS. Statistical analysis was performed with SPSS v25, the associations between PNI and clinicopathologic characteristics were analyzed using Pearson's χ2 test, survival curves were calculated with Kaplan-Meier method, and comparison among groups with log-rank. Proportional Cox model was used to perform multivariate analysis. A p value <0.05 was significant. Results. A total of 110 patients were included in the analysis, and classified into two groups: low and high PNI (ROC curve analysis showed an optimal cutoff value of 32.1). Median follow-up was 65 months. Mean PNI at diagnosis was 39.3 (SD 6.7). All patients had infiltrating ductal carcinoma, 15.5% had metastatic disease, 18.2% had triple negative breast cancer, 23.6% had HER 2 overexpression, and around 51% where positive for hormone receptors. Mean PNI in patients with locally advanced disease was significantly lower than in patients with localized disease, (p= 0.044), no other statistically significant associations were found between mean PNI and clinical characteristics. Median OS was not reached in the high PNI group vs 48.5 months (mo) in the low PNI group, while 5 -year OS rates were 89% and 41%, respectively (p= 0.03). The high PNI group had better DFS than the low PNI group (median DFS 65 mo vs 22.5 mo, 5-year DFS rates 65% vs 45% (p = 0.024). In univariate and multivariate analysis, triple negative histological subtype and low PNI were independent prognostic indicators for poor survival. Conclusion. High PNI in breast cancer patients is associated with superior DFS and OS. PNI is an independent prognostic factor for DFS and OS. PNI is an accessible prognosis factor that uses only regular laboratory assessment in patients with cancer. Citation Format: Pamela Denisse Soberanis-Piña, Edgar Varela-Santoyo, Andres Mauricio Arroyave-Ramirez, Hector Hugo Buerba-Vieregge, Daniel Motola-Kuba. Association of the prognostic nutritional index and survival of patients with breast cancer in a third-level care hospital in Mexico [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS6-57.
Carcinoma of the extrahepatic biliary tract accounts for <2% of all cancers. Neuroendocrine tumor of the extrahepatic bile duct is very rare, and there are <200 cases reported since 1959. The preoperative diagnosis is infrequent (5.12%). The definite diagnosis relies on postoperative pathology which utilized immunohistochemistry study on many biomarkers to diagnose the histological subtypes of neuroendocrine neoplasms, such as chromogranin A, synaptophysin, and neuron-specific enolase. When the primary tumor has no metastases, radical removal of the lesion appears as curative treatment. The treatment of the carcinoid syndrome or other functioning syndrome is the first priority. We report a case of a 12-year-old Mexican woman with neuroendocrine tumor of the extrahepatic bile duct (common bile duct neuroendocrine tumor) seen in our hospital. Resection of the common bile duct, cholecystectomy, end to side Roux-en-y hepaticojejunostomy, and portal lymphadenectomy was performed. A review of the pertinent literature was performed. Given the rarity of the disease, treatment principles are based mainly on retrospective series and case reports. We present the eighth case in adolescence in the literature.
<b><i>Background:</i></b> The treatment of kidney cancer usually involves surgery, and in some cases systemic therapy. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to control postsurgical pain in patients undergoing nephrectomy for renal cancer. Nevertheless, the association between these drugs and adverse postsurgical outcomes, including deterioration of renal function, is not fully established. <b><i>Methods:</i></b> This retrospective cohort study included patients >18 years old with kidney cancer undergoing nephrectomy between January 2006 and January 2018. The primary endpoint was to determine the impact of postsurgical analgesic therapy (NSAIDs vs. acetaminophen) on renal function and postsurgical complications. This study was approved by our scientific and bioethical committee. <b><i>Results:</i></b> One hundred patients were included in the final analysis. Clear-cell renal-cell carcinoma was the most frequent histologic subtype. Adequate acute pain control was accomplished in 91% of the patients during hospitalization. Twenty percent of the patients presented postsurgical complications. Bleeding-related complications were the most frequent (9%), followed by surgical-site infection (6%) and acute renal injury (6%). The administration of NSAIDs was not related to any postsurgical complication in comparison with the use of acetaminophen (21.3 vs. 17.9%, respectively). The length of hospital stay did not differ between patients treated with NSAIDs and those treated with acetaminophen (the average stay was 4 days for both groups, <i>p</i> = 0.32). <b><i>Conclusion:</i></b> The use of NSAIDs was not related to acute kidney injury, postsurgical complications, or prolonged hospital stay in patients with renal cancer undergoing nephrectomy.
Soft tissue sarcomas represent <1% of all neoplasms. Leiomyosarcomas comprise only 5–7% of cases, and only 2% of these are vascular. Vascular leiomyosarcomas are extremely rare and represent only 0.001% of all neoplasms, the venous type being up to 5 times more frequent. Arterial leiomyosarcomas most frequently affect the great vessels, being fatal in most cases. In the reported cases of arterial leiomyosarcomas, the most frequently affected site is the pulmonary artery. We present the clinical case of 2 patients (a 42-year-old woman and a 36-year-old man) with a diagnosis of arterial pleomorphic leiomyosarcoma that conditioned cardiac tamponade as the initial manifestation. As it is an exceptionally rare neoplasm and with few cases reported in the literature, it is important to identify and describe this pathology which, due to the impossibility of offering surgical treatment, represents a therapeutic challenge.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.